Arca
Skip to content
Tools
Tools

CFB: Complement factor B

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Precursor of the catalytic component of the C3 and C5 convertase complexes of the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CFB, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Iptacopan

Phase 30

    Phase 20

      Phase 10

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionMechanismOpen trialsWarnings
        IptacopanApprovedNovartis PharmaceuticalsSmall moleculeInhibitorComplement factor B inhibitor24Boxed warning

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainIptacopan—RecruitingNovartis Pharmaceuticals2026-05-20
        IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data CollectionIptacopan—Not yet recruitingNovartis Pharmaceuticals2026-03-18
        A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 GlomerulopathyIptacopan—RecruitingNovartis Pharmaceuticals2026-02-18
        Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic MicroangiopathyIptacopanNot applicableRecruitingFirst Affiliated Hospital of Zhejiang University2026-01-16
        CHART-C3G/CLNP023B12011Iptacopan—Not yet recruitingNovartis Pharmaceuticals2026-01-09
        REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaIptacopan—RecruitingNovartis Pharmaceuticals2025-11-14
        Fabhalta Capsules Specified Drug-use SurveyIptacopan—Active, not recruitingNovartis Pharmaceuticals2025-09-05
        Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANIptacopanPhase 3RecruitingNovartis Pharmaceuticals2025-05-29

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Atypical hemolytic-uremic syndrome with B factor anomaly
        0.76
        Atypical hemolytic-uremic syndrome
        0.70
        Immunodeficiency due to a complement cascade protein anomaly
        0.61
        Complement 3 glomerulopathy
        0.55
        Complement deficiency
        0.42
        Hemolytic-uremic syndrome
        0.37
        Primary membranoproliferative glomerulonephritis
        0.37
        Membranoproliferative glomerulonephritis
        0.37
        Atypical hemolytic uremic syndrome with complement gene abnormality
        0.37
        Neurodegenerative disease
        0.30

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5731, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P00751, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.